Forbes Health, Healthline, Leafly, Medical News Today, MJBizDaily — the cannabis and CBD publications AI engines cite most when buyers ask which products, brands, and stocks are best. First-edition spot capture across 12 buyer-intent queries on Google Search.
The CBD industry has matured. The early-stage growth wave of 2018–2022 is over. The brands that win in 2026 grow through strategic partnerships that expand reach into adjacent verticals — restaurants, hospitality, beauty, fitness, pet, sleep, beverage. The partnership categories that consistently work, the AI discovery layer shift, and why one-off campaigns lose to always-on multi-vertical infrastructure.
THC and CBD often appear in the same trade press and investor decks, but they operate under different regulatory frameworks, platform policies, distribution channels, and consumer expectations. Communications strategy that treats them interchangeably underperforms on both sides. The Schedule III April 2026 reclassification context, the THC vs CBD reality split, where the two categories diverge in distribution, and where they converge in discipline.
CBD is the federally legal cannabinoid that built a multi-billion-dollar parallel market — and the FDA enforcement reality that defines how the brands inside it are allowed to communicate. The CBD satellite to the cannabis communications pillar.
CBDistillery grew from $40M to projected $200M between 2018 and 2019. The CBD category never hit its $20B projection. What happened, where Balanced Health Botanicals sits in 2026, and what the case teaches about CBD marketing in the answer-engine era.
Cannabis is the only major U.S. consumer category where paid media is structurally locked out at the federal level. That removes one leg of the marketing tripod. Earned and owned are now mediated by AI engines. Citation Share is the channel. The 2026 pillar.
FDA Closer to Zero, the 2021 House Subcommittee heavy metals report, the 2022 Abbott Similac crisis, California AB 899 — the regulatory and trust architecture for baby formula and infant nutrition in 2026. Plus EPR's 10-criterion Infant Nutrition Product Safety Communications Checklist.
